REG - PureTech Health PLC - Transaction in Own Shares

Jefferies FinancialAnnouncement

09/01/2024 08:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240109:nRSI0132Za&default-theme=true

RNS Number : 0132Z  PureTech Health PLC  09 January 2024

9 January 2024

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the
following number of its ordinary shares of one pence each through Jefferies
International Limited ("Jefferies"), as part of its Share Buyback Programme,
details of which were announced on 9 May 2022.

 

 Date of purchase:                              8 January 2024

 Number of ordinary shares purchased:           26,079

 Highest price paid per share:                  207.50p

 Lowest price paid per share:                   204.00p

 Volume weighted average price paid per share:  206.97p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 17,878,951 ordinary
shares in treasury and has 271,589,208 ordinary shares in issue (excluding
treasury shares). The total number of voting rights in the Company is
therefore 271,589,208 which may be used by shareholders in their calculations
to determine if they are required to notify their interest in, or a change to
their interest in, PureTech Health plc under the FCA's Disclosure Guidance and
Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as
incorporated into UK domestic law by the European Union (Withdrawal) Act 2018)
(the Market Abuse Regulation), detailed information about the individual
purchases is available below.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life
to new classes of medicine to change the lives of patients with devastating
diseases. The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network of
scientists, clinicians and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D engine has
resulted in the development of 27 therapeutics and therapeutic candidates,
including two (Plenity® and EndeavorRx®) that have received both U.S.
FDA clearance and European marketing authorization and a third (KarXT) that
has been filed for FDA approval. A number of these programs are being advanced
by PureTech or its Founded Entities in various indications and stages of
clinical development, including registration enabling studies. All of the
underlying programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and then
advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com/)  or connect with us on X, formerly known as
Twitter, @puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

 

 Transaction Date  Transaction Time  Volume  Price (GBp)  Platform  Transaction Reference Number
 08/01/2024        08:14:57          940     207.5        CHIX      00384448243TRLO0.1.1
 08/01/2024        08:17:03          447     207          BATE      00384448722TRLO0.1.1
 08/01/2024        08:17:03          527     207          AQXE      00384448721TRLO0.1.1
 08/01/2024        08:17:03          247     207          TRQX      00384448723TRLO0.1.1
 08/01/2024        08:17:03          23      207          BATE      00384448724TRLO0.1.1
 08/01/2024        08:17:03          940     207          XLON      00384448725TRLO0.1.1
 08/01/2024        08:22:08          438     204.5        XLON      00384449832TRLO0.1.1
 08/01/2024        08:22:08          32      204.5        XLON      00384449833TRLO0.1.1
 08/01/2024        08:32:05          470     204          XLON      00384452038TRLO0.1.1
 08/01/2024        08:32:05          470     204          XLON      00384452039TRLO0.1.1
 08/01/2024        08:32:05          30      204          XLON      00384452040TRLO0.1.1
 08/01/2024        08:32:05          70      204          XLON      00384452041TRLO0.1.1
 08/01/2024        08:32:05          370     204          XLON      00384452042TRLO0.1.1
 08/01/2024        08:32:05          115     204          XLON      00384452043TRLO0.1.1
 08/01/2024        08:32:05          355     204          XLON      00384452044TRLO0.1.1
 08/01/2024        09:01:49          337     207.5        AQXE      00384456705TRLO0.1.1
 08/01/2024        09:01:49          52      207.5        BATE      00384456706TRLO0.1.1
 08/01/2024        09:01:49          500     207.5        XLON      00384456707TRLO0.1.1
 08/01/2024        09:01:49          232     207.5        CHIX      00384456709TRLO0.1.1
 08/01/2024        09:01:49          910     207.5        XLON      00384456708TRLO0.1.1
 08/01/2024        09:01:49          238     207.5        CHIX      00384456710TRLO0.1.1
 08/01/2024        09:01:49          35      207.5        BATE      00384456711TRLO0.1.1
 08/01/2024        09:01:49          40      207.5        BATE      00384456712TRLO0.1.1
 08/01/2024        09:01:49          343     207.5        BATE      00384456713TRLO0.1.1
 08/01/2024        09:03:51          247     207          TRQX      00384456990TRLO0.1.1
 08/01/2024        09:29:34          470     206          XLON      00384461485TRLO0.1.1
 08/01/2024        09:29:34          158     206          XLON      00384461486TRLO0.1.1
 08/01/2024        09:29:34          312     206          XLON      00384461487TRLO0.1.1
 08/01/2024        09:29:34          3       206          XLON      00384461488TRLO0.1.1
 08/01/2024        09:29:34          416     206          XLON      00384461490TRLO0.1.1
 08/01/2024        09:29:34          51      206          XLON      00384461489TRLO0.1.1
 08/01/2024        09:29:34          83      206          XLON      00384461491TRLO0.1.1
 08/01/2024        09:29:34          387     206          XLON      00384461492TRLO0.1.1
 08/01/2024        09:48:50          470     206.5        CHIX      00384465335TRLO0.1.1
 08/01/2024        10:03:48          125     207          XLON      00384467922TRLO0.1.1
 08/01/2024        10:04:23          66      207          XLON      00384467995TRLO0.1.1
 08/01/2024        10:05:19          54      207          XLON      00384468106TRLO0.1.1
 08/01/2024        10:05:39          25      207          XLON      00384468140TRLO0.1.1
 08/01/2024        10:06:15          36      207          XLON      00384468218TRLO0.1.1
 08/01/2024        10:50:34          1430    207.5        XLON      00384475873TRLO0.1.1
 08/01/2024        10:50:34          1675    207.5        XLON      00384475874TRLO0.1.1
 08/01/2024        10:50:34          349     207.5        XLON      00384475875TRLO0.1.1
 08/01/2024        10:50:42          300     207          CHIX      00384475901TRLO0.1.1
 08/01/2024        11:29:51          247     207.5        TRQX      00384481501TRLO0.1.1
 08/01/2024        11:29:51          170     207          CHIX      00384481502TRLO0.1.1
 08/01/2024        11:29:51          55      207          CHIX      00384481505TRLO0.1.1
 08/01/2024        12:59:44          58      207.5        TRQX      00384494199TRLO0.1.1
 08/01/2024        12:59:55          415     207.5        CHIX      00384494224TRLO0.1.1
 08/01/2024        12:59:55          432     207.5        AQXE      00384494223TRLO0.1.1
 08/01/2024        12:59:55          470     207.5        BATE      00384494225TRLO0.1.1
 08/01/2024        12:59:55          189     207.5        TRQX      00384494226TRLO0.1.1
 08/01/2024        12:59:55          940     207.5        XLON      00384494227TRLO0.1.1
 08/01/2024        13:18:52          470     207          XLON      00384496972TRLO0.1.1
 08/01/2024        13:18:52          67      207          XLON      00384496973TRLO0.1.1
 08/01/2024        13:18:52          234     207          XLON      00384496975TRLO0.1.1
 08/01/2024        13:18:52          403     207          XLON      00384496974TRLO0.1.1
 08/01/2024        13:18:52          236     207          XLON      00384496976TRLO0.1.1
 08/01/2024        13:18:52          30      207          XLON      00384496977TRLO0.1.1
 08/01/2024        13:18:52          440     207          XLON      00384496978TRLO0.1.1
 08/01/2024        15:51:30          470     207.5        BATE      00384553027TRLO0.1.1
 08/01/2024        15:51:30          30      207.5        BATE      00384553028TRLO0.1.1
 08/01/2024        15:56:08          432     207.5        AQXE      00384555512TRLO0.1.1
 08/01/2024        15:58:17          2       207.5        XLON      00384556616TRLO0.1.1
 08/01/2024        15:58:17          468     207.5        XLON      00384556617TRLO0.1.1
 08/01/2024        15:58:17          470     207.5        XLON      00384556618TRLO0.1.1
 08/01/2024        15:58:17          507     207.5        XLON      00384556619TRLO0.1.1
 08/01/2024        15:58:17          433     207.5        XLON      00384556620TRLO0.1.1
 08/01/2024        15:58:17          470     207.5        XLON      00384556621TRLO0.1.1
 08/01/2024        15:58:17          470     207.5        XLON      00384556622TRLO0.1.1
 08/01/2024        15:58:17          470     207.5        XLON      00384556623TRLO0.1.1
 08/01/2024        15:58:17          470     207.5        XLON      00384556625TRLO0.1.1
 08/01/2024        15:58:17          470     207.5        XLON      00384556624TRLO0.1.1
 08/01/2024        15:58:17          390     207.5        XLON      00384556626TRLO0.1.1
 08/01/2024        15:58:17          550     207.5        XLON      00384556627TRLO0.1.1
 08/01/2024        15:58:17          303     207.5        XLON      00384556628TRLO0.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSFLFVTLAITIIS